CCRM

On behalf of the CCRM Group of Companies, we wish you a wonderful holiday season and all the best in 2025! OmniaBio, LineaBio, CCRM Australia, CCRM Nordic, CATTI #CCRMEnterprises, #TheCCRMFoundation

Happy holidays to all ☃️ The November edition of my CCRM feature is here! Lots of interesting #regenerativemedicine headlines last month, so make sure to bookmark this one.

As you enjoy some much-earned downtime this Boxing Day, we have a new blog for you that captures the big #regenerativemedicine news stories from last month. Read Lyla El-Fayomi's blog here: https://lnkd.in/gWdxrq2x #GenevaPatient, #genetherapy, #AlzheimerDisease, #iPSCs, #AADC, #FDAapproval

The CCRM team had the pleasure of donating, packaging and delivering meals to WoodGreen Community Services, a leading social services agency in Toronto that we have been supporting over the past year. Happy holidays to WoodGreen's clients and you!

Season four of “Commercializing Living Therapies with CCRM” kicked off with Christopher P. Boone, PhD, Oracle, and Kenneth Harris, OmniaBio, discussing how artificial intelligence (AI) and robotics are shaping the biomanufacturing facility of the future. In this clip, Chris explains how AI’s data collection technologies help personalize treatments for patients. “One of the more fascinating things, and this is the world where I live, is just the literal access to all the different types of data that we have about the patient. Whether it be, certainly, the data that we capture in their electronic health record as they’re having these routine encounters with their providers, there’s also genetic/genomic data that exists, this environmental data that we capture, this lifestyle data that we particularly care about. All of these data sources feed into what it would take to make medicine much more personalized and ultimately start to get into what those patient preferences are. As Ken mentioned, with these 70+ therapies that are now on label, patients do, or should, feel a bit more empowered to select therapies where they’re willing to accept certain risks for certain benefits.” Listen wherever you stream podcasts, or at the following link: https://lnkd.in/daTWUkEF #artificialintelligence, #AI, #robotics #regenmed #cellandgenetherapies #podcast

As Benjamin Franklin once said... "An investment in knowledge pays the best interest." Looking for a job, new opportunities or more responsabilities in your current role, don't miss out on this opportunity!

A leading panel of experts provided their insights into the transformational potential of cell and gene therapies at BioEurope. Read our blog below. https://lnkd.in/eUqfjfeW The panel addressed a wide range of audience questions about how these innovative modalities could push the boundaries of medicine, but also the challenges around financing, manufacturing, scaling, and optimizing these complex technologies, for use as sophisticated, personalized products. Thanks to Romain Bonnot, Pharm.D at ZS for chairing the lively interactive session, with panellists Celine Carlet at Galapagos, Michael May at CCRM, and Reagan Jarvis at Anocca. Organised by Informa Connect Life Sciences and EBD Group. Daniel Gooch Katja Stout #biotech #pharma #lifesciences #BioEurope2024 #celltherapy #communications

Blogger Sara Nolte reports on new Canadian cancer immunotherapy developments. As she writes, "We’ve already seen some great stuff with CAR T cells and checkpoint inhibitors. But the strength of these therapies is also their downfall: their targets make them highly specific and powerful against tumours expressing and exploiting the targets, but also limit the use of the therapies to those specific tumours. What if rather than making cancer-specific therapies, we made therapy-specific tumours?" That’s exactly what a team led by Drs. John Bell and Jean-Simon Diallo, The Ottawa Hospital, have done. "Oh, how the tables have turned!" Read: Ottawa researchers make tumour-marker negative cancers positive with oncolytic viruses https://lnkd.in/dG--nPXX cc: Virica Biotech

Insights That Shaped 2024: “Thanks to regenerative medicine research happening in Toronto, I believe cancer’s days are numbered.”  - Dr. Michael May, President and CEO of the CCRM at our Life Sciences Breakfast 

The #SummerbyDesign deadline is approaching in 3 days! Don't miss your chance to apply for the international program that gives PhD students & post-docs the skills to commercialize #regenmed. Hosted by #MedicinebyDesign, CCRM, Stem Cell Network, University of Toronto - Rotman School of Management. Learn more & apply: https://lnkd.in/gNs5_t_4